Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Related Classes & Events

Neuroscience Institute

Clinical Research

DOMINION Study 248.619


Description: 
A cross-sectional, retrospective screening and case-control study examining the frequency of, and risk factors associated with, impulse control disorders in Parkinson’s disease patients treated with MIRAPEX® (pramipexole) and other anti-parkinson agents

Design: 
A cross-sectional, retrospective screening and case-control study

Eligibility: 
Parkinson patients on dopamine agonists

Sponsor: 
Boehringer Ingelheim Pharmaceuticals, Inc.

Contact: 
Renee Pfeiffer CRNP, 412-359-8860


SLV308


Description: 
A Randomized, Double-blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s disease

Design: 
Randomized, Double blind, Placebo Controlled Parallel-group Fixed and Flexible SLV308 Dose Arm Study

Eligibility: 
New onset Parkinson patients not on medication

Sponsor: 
Solvay Pharmaceuticals

Contact: 
Renee Pfeiffer CRNP, 412-359-8860

 

 

X
West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)











Did you find what you were looking for?


Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 9 + 4 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.